



MRCOG EDGE
RIGHT PLACE TO LEARN


Maternal Medicine

MRCOG Part 2

What you need to know

Maternal Medicine
MRCOG Part 2





**Know your enemy and
know yourself and you
can fight a hundred
battles without
disaster.**

Sun Tzu

MRCOG

Syllabus and Knowledge Requirements for Core Curriculum 2019

Knowledge Area 6 – Maternal medicine

CiP	CiP Description
1	The doctor is able to apply medical knowledge, clinical skills and professional values for the provision of high-quality and safe patient-centred care
6	The doctor takes an active role in helping self and others to develop
12	The doctor is competent in recognising, assessing non-emergency obstetrics care

Summary Knowledge Requirements

PART 1 MRCOG

- Epidemiology and pathological processes that underlie common maternal diseases in pregnancy, including diabetes and endocrine, respiratory, cardiac and haematological disease
- Pathophysiology and presentation of common infections that affect pregnant women and the treatments and interventions used for these infections
- Drugs used to treat maternal disease, and the potential maternal and fetal complications associated with their use
- Imaging methods used to screen for maternal and fetal complications of maternal disease, e.g. ultrasound, X-ray and magnetic resonance imaging, and how to interpret their results

PART 2 MRCOG

- Have a good understanding of common medical disorders and the effect that pregnancy may have on them, as well as the effect of such disorders on pregnancy (this includes both medical and obstetric problems)
- Demonstrate your ability to assess and treat these conditions and liaise with colleagues in other specialties

In detail, you need

1. Epidemiology
2. Aetiology
3. Pathophysiology
4. Clinical characteristics
5. Prognosis
6. Management

1. Hypertension
2. Kidney – UTI, pyelonephritis, CKD, renal stones, transplantation, AKI
3. Heart – Congenital, Rheumatic, Ischaemic, Cardiomyopathy, HF
4. Liver – Cholestasis, Hepatitis, Acute fatty degeneration, Gallstones
5. Circulatory – Coagulation defects, Thrombocytopenia, Thromboembolism, Transfusion, Replacement of blood, Varicose Veins
6. Pulmonary – Asthma, Infection, Embolism, Aspiration
7. (list goes for another 12 more)

Hypertension in pregnancy: diagnosis and management

NICE guideline
Published: 25 June 2019
Last updated: 17 April 2023

Diabetes in pregnancy: management from preconception to the postnatal period

NICE guideline
Published: 25 February 2015
Last updated: 16 December 2020

NICE Guidelines

Recurrent Miscarriage

Green-top Guideline No. 17

The Management of Women with Red Cell Antibodies during Pregnancy

Green-top Guideline No. 65
May 2014

Management of Sickle Cell Disease in Pregnancy

Green-top Guideline No. 61
July 2011

Green Top Guidelines

Epilepsy in Pregnancy

Green-top Guideline No. 68
June 2016

The diagnosis and treatment of malaria in pregnancy

Green-top Guideline No. 54b
April 2010

Chickenpox in Pregnancy

Green-top Guideline No. 13
January 2015

Management of Beta Thalassaemia in Pregnancy

Green-top Guideline No. 66
March 2014

Bacterial Sepsis following Pregnancy

Green-top Guideline No. 64b
April 2012

Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management

Green-top Guideline No. 37b
April 2015

© 2013 Pearson Education, Inc. or its affiliate(s). All rights reserved. Pearson Education, Inc., publishing as Pearson Benjamin Cummings, 101 Philip Drive, Assinippi Park, New York, NY 10964-2135



Intrapartum care for women with existing medical conditions or obstetric complications and their babies

NICE guideline
Published: 6 March 2019
[nice.org.uk/guidance/ng121](https://www.nice.org.uk/guidance/ng121)

Contents

Overview	6
Who is it for?	6
Recommendations	7
1.1 Information for women with existing medical conditions	7
1.2 Planning for intrapartum care with women with existing medical conditions – involving a multidisciplinary team.....	8
1.3 Heart disease.....	9
1.4 Asthma.....	20
1.5 Long-term systemic steroids.....	20
1.6 Bleeding disorders	21
1.7 Subarachnoid haemorrhage or arteriovenous malformation of the brain	25
1.8 Acute kidney injury or chronic kidney disease.....	27
1.9 Obesity.....	30
1.10 Information for women with obstetric complications or no antenatal care	32
1.11 Risk assessment for women with obstetric complications or no antenatal care.....	33
1.12 Pyrexia.....	36
1.13 Sepsis	36
1.14 Intrapartum haemorrhage	42
1.15 Breech presenting in labour	45
1.16 Small-for-gestational-age baby	46
1.17 Large-for-gestational-age baby	46
1.18 No antenatal care.....	47
1.19 Previous caesarean section	50
1.20 Labour after 42 weeks of pregnancy.....	52

Relevant physiology


	5%	TPR
	10%	DBP
	20%	HR
	30%	SV
	40%	CO
	50%	PV
	18-25%	RBC

Table 2.3 – Pregnancy-associated risk with different cardiac disease

Heart disease

- Multidisciplinary team
- Share care decision
- mWHO or NYHA
- Mechanical or Biological heart valve?

Low risk	Small increased risk of mortality/ moderate increased risk of morbidity	Moderate increased risk of mortality or severe morbidity	Significant increased risk of mortality or severe morbidity	Extremely high risk of mortality or severe morbidity
2.5%–5% risk cardiac event	5%–10% risk cardiac event	10%–19% risk cardiac event	19%–27% risk cardiac event	40%–100% risk cardiac event
Uncomplicated small or mild PS, PDA, MVP	Unrepaired ASD, VSD	Mild LV dysfunction (LVEF >45%), HCM	Moderate LV dysfunction (LVEF 30%–45%) Previous PPCM with normal LVEF Mechanical valves	PAH Severe LV impairment (<30%), NYHA III/IV Previous PPCM with any residual LV impairment
Successfully repaired ASD, VSD, PDA, APVD	Repaired tetralogy of Fallot	Repaired coarctation AVSD	Systemic RV with normal–mild ventricular dysfunction Fontan circulation	Systemic RV with moderate–severe ventricular dysfunction Fontan with complication
Atrial and ventricular ectopic beats	Most arrhythmias (e.g. SVT) Turner syndrome without aortopathy	Most native or tissue valve disease (except those in extremely high risk) e.g. mild MS, moderate AS	Unrepaired cyanotic congenital heart disease (without PAH) Moderate MS/severe asymptomatic AS	Severe MS/symptomatic AS Severe aortic (re) coarctation
		Marfan syndrome or other HTAD without aortic dilation Aorta <45 mm in bicuspid AoV	Aorta 40–45 mm in Marfan syndrome or other HTAD Aorta 45–50 mm in bicuspid AoV, Turner syndrome ASI 20–25 mm/m ² , tetralogy of Fallot <50 mm Ventricular tachycardia	Aorta >45 mm in Marfan syndrome or other HTAD aorta >50 mm in bicuspid AoV, Turner syndrome ASI >25 mm/m ² , tetralogy of Fallot >50 mm Vascular EDS

Which condition has the highest risk of maternal morbidity or death?

- a. Heart transplant recipient
- b. Marfan Syndrome with an aortic root measurement of 4cm
- c. Mechanical prosthetic heart valve
- d. Repaired tetralogy of Fallot
- e. Wolff-Parkinson-White Syndrome

Which condition has the highest risk of maternal morbidity or death?

- a. Heart transplant recipient
- b. Marfan Syndrome with an aortic root measurement of 4cm
- c. Mechanical prosthetic heart valve**
- d. Repaired tetralogy of Fallot
- e. Wolff-Parkinson-White Syndrome

Mechanical heart valve

- Stop warfarin 36w or 2w before delivery
- Start LMWH 24 hours after, aim anti-Xa levels:
 - 0.6 IU/ml (trough)
 - 1.0 – 1.2 IU/ml (peak, 3 to 4 hrs later)
 - Recheck weekly once target achieved
- LMWH – withhold 24 hours – 30 hours before delivery
- UH – withhold 4 to 6 hours before delivery
- Restart Warfarin 7 days post delivery

IE Prophylaxis

Remember H I V V S

- Hypertrophic cardiomyopathy
- Infective Endocarditis
- Valvular heart disease / valve replacement
- Structural heart disease (exclude isolated ASD, repaired VSD)

Second commonest indirect cause of maternal death?

- a. COVID-19
- b. Sepsis
- c. PPH
- d. Embolism
- e. Suicide
- f. Epilepsy
- g. Cardiac


Second commonest direct cause of maternal death?

- a. COVID-19
- b. Sepsis
- c. PPH
- d. Embolism
- e. Suicide
- f. Epilepsy
- g. Cardiac

Figure 2.3: Maternal mortality by cause 2018-20


MMBRACE-UK

Direct: VTE, PSY, Sepsis



Indirect: Cardiac, COVID, Neuro

Most women died
in the postnatal
period **86%**



MMBRACE-UK



MRCOG EDGE
RIGHT PLACE TO LEARN

Key messages


from the surveillance report 2023



2019-21, **241 women died** during or up to six weeks after pregnancy among 2,066,997 women giving birth in the UK.

10.1 women per 100,000 died during pregnancy or up to six weeks after birth or the end of pregnancy.


Causes of women's deaths




When maternal deaths due to COVID are excluded, **10.1 women** per 100,000 died during pregnancy or up to six weeks after childbirth or the end of pregnancy.

Inequalities in maternal mortality

Ethnic group



Living in more deprived areas




Key messages

from the themed morbidity



Recognition and management of bleeding

Assess blood loss early and regularly



Don't rely on a single measurement of clotting or haemoglobin




Consider and exclude concealed bleeding

Pulse rate and blood pressure are typically maintained until 30% of circulating volume is lost



A **raised pulse rate** or **drop in blood pressure** should prompt clinical evaluation of blood loss

National recommendation

Manage operating teams for **urgent** and **elective** caesarean sections separately



Category 1-3



Category

at pregnant, recently pregnant, and breastfeeding women the same as a non-pregnant person unless there is a very clear reason not to

Prepare a route for rapid delivery of advice and data on new vaccines and treatments




Include in medical and vaccine research

Tailor care after pregnancy to woman's individual needs



Equity for pregnant and breastfeeding women



Include guidance on admission to ECMO service

*ECMO = Extracorporeal membrane oxygenation



Ensure staff in internal medicine networks have the skills to care for complex physical, mental and social care needs



Develop training resources to promote shared decision making and counselling on medication use

A woman presented with palpitations. She describes as fast heartbeat which last about 5 to 10 minutes and occur roughly once a week. They can come on suddenly at any time. She hasn't blacked out with them, but feels anxious when they happen. She hasn't any heart problems before, but her father had a heart attack aged 55. There is no other family history of note

- a. Anxiety
- b. Atrial fibrillation
- c. Ectopic beats
- d. Supraventricular tachycardia
- e. Ventricular tachycardia

A woman presented with palpitations. She describes as fast heartbeat which last about 5 to 10 minutes and occur roughly once a week. They can come on suddenly at any time. She hasn't blacked out with them, but feels anxious when they happen. She hasn't any heart problems before, but her father had a heart attack aged 55. There is no other family history of note

- a. Anxiety
- b. Atrial fibrillation
- c. Ectopic beats
- d. Supraventricular tachycardia**
- e. Ventricular tachycardia

An obese 39-year-old smoker is admitted with chest pain at 34 weeks' gestation. She refused LMWH as she doesn't want to self-inject. The pain came on suddenly and has been present for 90 minutes so far. It radiates to her back, between her shoulder blades. She also has some pins and needles in one arm. The midwife noticed that her blood pressure is different in the two arms. On examination a harsh systolic murmur is heard.

- a. Aortic dissection
- b. Costochondritis
- c. Indigestion
- d. Myocardial ischaemia
- e. Pulmonary embolism

An obese 39-year-old smoker is admitted with chest pain at 34 weeks' gestation. She refused LMWH as she doesn't want to self-inject. The pain came on suddenly and has been present for 90 minutes so far. It radiates to her back, between her shoulder blades. She also has some pins and needles in one arm. The midwife noticed that her blood pressure is different in the two arms. On examination a harsh systolic murmur is heard.

- a. Aortic dissection**
- b. Costochondritis
- c. Indigestion
- d. Myocardial ischaemia
- e. Pulmonary embolism

- a.Folic acid 400mcg 1 month pre conception until 12 weeks
- b.Folic acid 400mcg 3 months pre conception until 12 weeks
- c.Folic acid 400mcg 1 month pre conception until 28 weeks
- d.Folic acid 400mcg 3 months pre conception until 28 weeks
- e.Folic acid 400mcg 1 month pre conception until 36 weeks
- f.Folic acid 400mcg 3 months pre conception until 36 weeks
- g.Folic acid 1mg 1 month pre conception until 12 weeks
- h.Folic acid 1mg 3 months pre conception until 12 weeks
- i.Folic acid 1mg 1 month pre conception until 28 weeks
- j.Folic acid 1mg 3 months pre conception until 28 weeks
- k.Folic acid 1mg 1 month pre conception until 36 weeks
- l.Folic acid 1mg 3 months pre conception until 36 weeks
- m.Folic acid 5mg 1 month pre conception until 12 weeks
- n.Folic acid 5mg 3 months pre conception until 12 weeks
- o.Folic acid 5mg 1 month pre conception until 28 weeks
- p.Folic acid 5mg 3 months pre conception until 28 weeks
- q.Folic acid 5mg 1 month pre conception until 36 weeks
- r.Folic acid 5mg 3 months pre conception until 36 weeks



1. Maternal obesity 2. Type 1 DM
3. Type 2 DM 4. Epilepsy on treatment
5. Valvular heart disease on treatment
6. Sickle cell anemia 7. Alpha
thalassemia 8. Beta thalassemia 9. Iron
deficiency anemia

1.3.2.1 Pregnant women (and those intending to become pregnant) should be informed that dietary supplementation with folic acid, before conception and throughout the first 12 weeks, reduces the risk of having a baby with a neural tube defect (for example, anencephaly or spina bifida). The recommended dose is 400 micrograms per day.



4.2 *What nutritional supplements should be recommended to women with obesity who wish to become pregnant?*

Women with a BMI 30 kg/m² or greater wishing to become pregnant should be advised to take 5 mg folic acid supplementation daily, starting at least 1 month before conception and continuing during the first trimester of pregnancy.

1.1.11 Advise women with diabetes who are planning to become pregnant to take folic acid (5 mg/day) until 12 weeks of gestation to reduce the risk of having a baby with a neural tube defect. [2008]

periconceptional folate (108, 95% CI 106–111) ($P = 0.0009$).¹⁵ Given the potential benefit of folate on long-term cognitive outcomes, the known safety of the supplement and the absence of evidence of its ineffectiveness in preventing major congenital malformation, it is advised that WGE are prescribed high-dose folic acid 5 mg daily from at least 3 months prior to conception to the end of the first trimester.

4.5 *What vitamin supplements should be given?*

Folic acid (5 mg) should be given once daily both preconceptually and throughout pregnancy.

Folic acid is recommended in all pregnant women to prevent neural tube defects.³⁹

Folic acid at a dosage of at least 1 mg daily is recommended for women with SCD outside pregnancy in view of their haemolytic anaemia, which puts them at increased risk of folate deficiency.⁴⁰

Folic acid 5 mg daily should be prescribed during pregnancy to reduce the risk of neural tube defect and to compensate for the increased demand for folate during pregnancy.⁴¹

4.7 *What vitamin supplements should be recommended?*

Folic acid (5 mg) is recommended preconceptually to all women to prevent neural tube defects.

Women with thalassaemia have a much higher demand for folic acid so high-dose supplementation is needed. Folic acid 5 mg daily should be commenced 3 months prior to conception.^{42,43}

A woman with history of asthma attends clinic at 36 weeks. BP 145/85, Proteinuria -ve. She has ankle oedema. She is treated with Labetalol. She becomes breathless

- a. Anxiety
- b. Aortic stenosis
- c. Asthma
- d. Flu
- e. Hypertrophic cardiomyopathy
- F) Mitral stenosis
- G) Peripartum cardiomyopathy
- H) Pneumonia
- I) Pre-eclampsia

A woman with history of asthma attends clinic at 36 weeks. BP 145/85, Proteinuria -ve. She has ankle oedema. She is treated with Labetalol. She becomes breathlessness

- a. Anxiety
- b. Aortic stenosis
- c. Asthma**
- d. Flu
- e. Hypertrophic cardiomyopathy
- F) Mitral stenosis
- G) Peripartum cardiomyopathy
- H) Pneumonia
- I) Pre-eclampsia



A South-east Asia woman becomes breathless 12 hours after delivery of her first child. She had epidural in labour, kept well-hydrated because of pyrexia and had syntometrine for third stage. She is coughing up pink frothy sputum

- a. Anxiety
- b. Aortic stenosis
- c. Asthma
- d. Flu
- e. Hypertrophic cardiomyopathy

- F) Mitral stenosis
- G) Peripartum cardiomyopathy
- H) Pneumonia
- I) Pre-eclampsia

A South-east Asia woman becomes breathless 12 hours after delivery of her first child. She had epidural in labour, kept well-hydrated because of pyrexia and had syntometrine for third stage. She is coughing up pink frothy sputum

- a. Anxiety
- b. Aortic stenosis
- c. Asthma
- d. Flu
- e. Hypertrophic cardiomyopathy

F) Mitral stenosis

- G) Peripartum cardiomyopathy
- H) Pneumonia
- I) Pre-eclampsia

A 40-year-old African woman with an IVF twin pregnancy at 35w is admitted with a cough. HR 110bpm, RR 25/min. Refuses to lie down as it makes her more breathless. She has attended frequently during pregnancy because she is very worried about fetal wellbeing. She has ankle oedema and is agitated.

- a. Anxiety
- b. Aortic stenosis
- c. Asthma
- d. Flu
- e. Hypertrophic cardiomyopathy

- F) Mitral stenosis
- G) Peripartum cardiomyopathy
- H) Pneumonia
- I) Pre-eclampsia



A 40-year-old African woman with an IVF twin pregnancy at 35w is admitted with a cough. HR 110bpm, RR 25/min. Refuses to lie down as it makes her more breathless. She has attended frequently during pregnancy because she is very worried about fetal wellbeing. She has ankle oedema and is agitated.

- a. Anxiety
- b. Aortic stenosis
- c. Asthma
- d. Flu
- e. Hypertrophic cardiomyopathy

- F) Mitral stenosis
- G) **Peripartum cardiomyopathy**
- H) Pneumonia
- I) Pre-eclampsia



Table 16.1 – Breathlessness

Differential diagnosis	Important clinical features	Investigations
Physiological	Can occur at any stage of pregnancy, but is most common in the last trimester. May be most apparent at rest or when speaking	This is a diagnosis of exclusion, which common should only be made once the other diagnoses have been considered
Anaemia ^a	May not cause symptoms until severe. May be associated with lethargy	Full blood count
Asthma ^b	Often associated with cough and/or wheezy breathing Symptoms are usually worse at night and on waking or after exercise	The diagnosis is usually made on the basis of history PEFR may be normal in clinic If there is doubt about the diagnosis, measure her own PEFR at home (morning and evening) and look for diurnal variation and morning peak expiratory flow rate (PEFR) > 20% FeNO (fractional concentration of expired nitric oxide) Response to inhaled bronchodilators is a confirmatory feature
Pulmonary embolus ^c	Onset is usually sudden and associated with pleuritic or central (large pulmonary embolus) chest pain. Worse on exercise and may be associated with haemoptysis. Look for associated sinus tachycardia, raised JVP. A high index of suspicion is needed and this diagnosis should always be considered in a pregnant or postpartum woman with breathlessness, chest pain or syncope The risk is higher in obese, older women, post-caesarean section or surgery and in those with previous thromboembolism or thrombophilia	ECG (sinus tachycardia, tall peaked p-waves) Right heart strain (S ₁ , Q ₃ , T ₃) may be seen in pregnancy Chest x-ray (often normal but may show hyperinflation, oligoemia, wedge-shaped infiltrate) Arterial blood gases (hypoxaemia and hypercapnia) The diagnosis should be confirmed with CT scan, CTPA or echocardiogram

Cardiac causes^d

There are many cardiac causes of breathlessness; most are uncommon and only two are discussed here

Mitral stenosis^d

Consider in migrant women
Breathlessness is due to pulmonary oedema. Women may have been asymptomatic at the beginning of pregnancy
Ask about orthopnoea, paroxysmal nocturnal dyspnoea and haemoptysis
The mid-diastolic murmur may be difficult to hear. Look for associated sinus tachycardia
Pulmonary oedema in association with mitral stenosis is a particular risk immediately following delivery. NB. Pulmonary oedema may cause wheeze on auscultation 'cardiac asthma'

ECG
Echocardiogram
Chest x-ray

Peripartum cardiomyopathy (PPCM) or decompensated pre-existing dilated cardiomyopathy^d

PPCM most common in the first month after delivery, but can present antenatally
More common in older, multiparous black women and women with multiple pregnancy, pre-eclampsia or hypertension
Symptoms and signs of biventricular failure i.e. tachycardia, pulmonary oedema and peripheral oedema. NB. Pulmonary oedema may cause wheeze on auscultation 'cardiac asthma'

ECG
Echocardiogram
Chest x-ray
BNP

How disease get affected and vice versa



Asthma

- 1/3 improves, 1/3 maintain, 1/3 worsens (TOG 2013) Pregnancy does
- not influence the severity of asthma (HOM 2021) The risk of atopic
- disease developing in the child of a woman with asthma is about 1 in 10 or 1 in 3 if both parents are atopic PGE1 and PGE2 is safe. Avoid
- PGF2 α .
- Most antibiotics are safe to use in pregnancy and during lactation; caution is required with aminoglycosides, tetracycline and quinolones (e.g. ciprofloxacin, levofloxacin)



Epilepsy

- Pregnancy does not affect the frequency
- Women who have been seizure free for >9 months pre pregnancy, 75% remain seizure free in pregnancy
- All AED can cross placenta. Most teratogenic is sodium valproate. Lower risk one are: Carbamazepine, Lamotrigine, Levetiracetam
- TENS, Epidural, Diamorphine are safe in labour. Avoid using Pethidine

SLE

- 50% likelihood of flare (skin and joints), especially puerperium period
- Rule of 30
 - 30% risk of renal flare
 - 30% risk of pre-eclampsia
 - 30% risk of preterm delivery and low birthweight
 - 30% patients are anti-Ro/La positive
 - 30 – 40% have aPLs
- ACTH is safe in pregnancy. MM is teratogenic
 - Azathioprine, Cyclosporin, Tacrolimus, Hydroxychloroquine
 - Methotrexate, Mycophenolate Mofetil



SLE

- In babies of anti Ro/La positive mothers, risk of transient cutaneous lupus is ~5% and risk of CHB ~2%
- If previous 1 child has CHB, risk for current child 16 – 18%
- If previous 2 children has CHB, risk for current child 50%



Skin eruptions specific to pregnancy: an overview

Table 1. Dermatoses of pregnancy

Dermatoses of pregnancy	Areas affected	Risk factors	Recurrence risk	Management	Pregnancy outcome
Intrahepatic cholestasis of pregnancy	Scalp, anus, vulva and abdominal skin	Indian–Asian or Pakistani–Asian ethnic origin, previous obstetric cholestasis	60–70% in future pregnancies	Ursodeoxycholic acid Topical emollients Sedating antihistamines ? Water-soluble vitamin K	? Increased risk of stillbirth ? Increased risk of PPH ? Increased risk of fetal distress Increased risk of premature birth (mostly iatrogenic), meconium passage and caesarean section
Atopic eruption of pregnancy	Face, neck, chest and extensor surfaces of the limbs and trunk	Family history of atopy	Limited data	Topical emollients Topical anti-pruritics Topical steroids Antihistamines Ultraviolet light Topical acne treatment	No adverse effect on mother or fetus
Polymorphic eruption of pregnancy	Abdominal striae with periumbilical sparing Can progress to trunk and extremities, sparing palms, soles and face	Nulliparity, multiple pregnancies Any cause of overdistension of skin	Rarely recurs	Topical steroids (first-line) Topical emollients Antihistamines Oral steroids	No adverse effect on mother or fetus
Pemphigoid gestationis	Appears around umbilicus unlike PEP Can progress to trunk, extremities, palms and soles with mucosal sparing	Recognised correlation with the haplotypes HLA-DR3 and HLA-DR4 Other autoimmune conditions	May recur in subsequent pregnancies, with earlier onset and increasing severity Also may recur with oral contraception/ menstruation	Topical/oral corticosteroids Antihistamines Antibiotics Immunophoresis Immunosuppressants	IUGR ? Preterm labour Self-limiting skin lesions in neonate

IUGR = intrauterine growth restriction; PEP = polymorphic eruption of pregnancy; PPH = Postpartum haemorrhage; ? = limited evidence

Asthma – When do you need IV Hydrocortisone?

- a. When patient on MDI Salbutamol
- b. When patient on MDI Salbutamol and Budesonide
- c. When patient on MDI Salbutamol and Seretide
- d. When patient on Montelukast 5mg OD for 2 weeks
- e. When patient on Montelukast 5mg OD for 3 weeks
- f. When patient on Montelukast 10mg OD for 2 weeks
- g. When patient on Montelukast 10mg OD for 3 weeks
- h. When patient on Prednisolone 5mg OD for 2 weeks
- i. When patient on Prednisolone 5mg OD for 3 weeks
- j. When patient on Prednisolone 10mg OD for 2 weeks
- k. When patient on Prednisolone 10mg OD for 3 weeks



Asthma – When do you need IV Hydrocortisone?

- a. When patient on MDI Salbutamol
- b. When patient on MDI Salbutamol and Budesonide
- c. When patient on MDI Salbutamol and Seretide
- d. When patient on Montelukast 5mg OD for 2 weeks
- e. When patient on Montelukast 5mg OD for 3 weeks
- f. When patient on Montelukast 10mg OD for 2 weeks
- g. When patient on Montelukast 10mg OD for 3 weeks
- h. When patient on Prednisolone 5mg OD for 2 weeks
- i. When patient on Prednisolone 5mg OD for 3 weeks**
- j. When patient on Prednisolone 10mg OD for 2 weeks
- k. When patient on Prednisolone 10mg OD for 3 weeks



L5.2 For women planning a vaginal birth who have adrenal insufficiency or who are taking long-term oral steroids (equivalent to 5 mg or more prednisolone daily for more than 3 weeks):

- continue their regular oral steroids and
- when they are in established first stage of labour, add intravenous or intramuscular hydrocortisone and consider a minimum dose of 50 mg every 6 hours until 6 hours after the baby is born.

L5.3 For women having a planned or emergency caesarean section who have adrenal insufficiency or who are taking long-term oral steroids (equivalent to 5 mg or more prednisolone daily for more than 3 weeks):

- continue their regular oral steroids and
- give intravenous hydrocortisone when starting anaesthesia; the dose will depend on whether the woman has received hydrocortisone in labour, for example:
 - consider giving 50 mg if she has had hydrocortisone in labour
 - consider giving 100 mg if she has not had hydrocortisone in labour
- give a further dose of hydrocortisone 6 hours after the baby is born (for example, 50 mg intravenously or intramuscularly).



Inherited disease

- Autosomal dominant
- Autosomal recessive
- X-link dominant
- X-link recessive



Inheritance

Auto Dom

Auto Rec

X-link Dom

X-link Rec

BPV
DOMINANT
HUMANS

ABCDEFGH
SWEATING

ARIF

DR GH

AD = BPV DOMINANT HUMANS

- BRCA
- Pseudo-hypoparathyroidism
- Von Willebrand
- Hypercholesterolemia
- Huntington's
- Hypertrophic obstructive
- cardiomyopathy
- HNPCC
-
- Dystrophia myotunica
- Osteogenesis Imperfecta
- Marfan Syndrome
- Intermittent porphyria
- Neurofibromatosis
- Achondroplasia / Adult polycystic kidney
- Noonan Syndrome
- Tuberous Sclerosis



AS = ABCDEFGH SWEATING

- Albinism
- Beta thalassemia
- CAH CF
- Distal spinal muscular atrophy
- Emphysema
- Friedreich ataxia
- Galactosaemia
- Haemochromatosis / Homocystinuria
- Sickle cell, Wilson, Tay Sach's disease



X-D = ARIF

- Alport Syndrome
- Rett Syndrome
- Incontinentia pigmenti
- Fragile X Syndrome

X-S = Doctor GH (DRGH)

- DMD
- Red-Green Blindness
- G6PD
- Haemophilia A & B





Victorious warriors win first and
then go to war, while defeated
warriors go to war first and then
seek to win.

~ Sun Tzu

AZ QUOTES



MRCOG EDGE
RIGHT PLACE TO LEARN

- a.Acyclovir 200mg TDS from 28w until delivery
- b.Acyclovir 200mg TDS from 32w until delivery
- c.Acyclovir 200mg TDS from 34w until delivery
- d.Acyclovir 200mg TDS from 36w until delivery
- e.Acyclovir 200mg QID from 28w until delivery
- f.Acyclovir 200mg QID from 32w until delivery
- g.Acyclovir 200mg QID from 34w until delivery
- h.Acyclovir 200mg QID from 36w until delivery
- i.Acyclovir 400mg TDS from 28w until delivery
- j.Acyclovir 400mg TDS from 32w until delivery
- k.Acyclovir 400mg TDS from 34w until delivery
- l.Acyclovir 400mg TDS from 36w until delivery
- m.Acyclovir 400mg QID from 28w until delivery
- n.Acyclovir 400mg QID from 32w until delivery
- o.Acyclovir 400mg QID from 34w until delivery
- p.Acyclovir 400mg QID from 36w until delivery



- Madam A, treated for genital herpes at 12w pregnancy
- Madam B, completed treatment for genital herpes at 28+1
- Madam C, diagnosed genital herpes at 5w and 15w, currently 25w pregnancy
- Madam D, diagnosed HIV and genital herpes last year, currently 28w pregnancy